InvestorsObserver
Sign Up Login

TXMD Therapeuticsmd Inc

$6.67 $-0.27 (-3.89%)
Add to Watchlist Compare
Overall

TXMD Stock Analysis Overview

What this means: InvestorsObserver gives Therapeuticsmd Inc (TXMD) an overall rank of 31, which is below average. Therapeuticsmd Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 31 means that 69% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

TXMD Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

TXMD Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

TXMD Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

TXMD Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

TXMD Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

TXMD Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

TXMD Stock Analysis Overview

What this means: InvestorsObserver gives Therapeuticsmd Inc (TXMD) an overall rank of 31, which is below average. Therapeuticsmd Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 31 means that 69% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full TXMD report

TXMD Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

TXMD Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

TXMD Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

TXMD Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

TXMD Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

TXMD Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Therapeuticsmd Inc (TXMD) Analyst Forecast

TXMD Price, Volume, Earnings, and Dividend Date

  • Last Price $6.67
  • Previous Close $6.94
  • Change $-0.27
  • Open $6.83
  • Volume 45,751
  • Avg. Volume (100-day) 989,795
  • Market Cap 63,145,584
  • Days Range 6.59 - 6.99
  • 52-week Range 1.99 - 40.9
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 11/10/22
  • Sector Healthcare
  • Industry Drug Manufacturers - Specialty & Generic
  • Avg. Analyst Rec. Premium
  • Beta 1.363
  • PEG Ratio —

Therapeuticsmd Inc (TXMD) Company Description

TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.

Therapeuticsmd Inc (TXMD) Stock Chart

View Interactive TXMD chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Drug Manufacturers - Specialty & Generic

Company Price
Optinose Inc (OPTN) (OPTN) $3.58
Avadel Pharmaceuticals Plc ADR (AVDL) (AVDL) $5.73
Societal Cdmo Inc (SCTL) (SCTL) $1.56
Assertio Therapeutics Inc (ASRT) (ASRT) $2.31
Sndl Inc (SNDL) (SNDL) $2.26
Alimera Sciences Inc (ALIM) (ALIM) $5.73
Harrow Health Inc (HROW) (HROW) $11.50
Lantheus Holdings (LNTH) (LNTH) $77.67
Evolus Inc (EOLS) (EOLS) $8.85
Teva Pharmaceutical Industries L (TEVA) (TEVA) $8.84